These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 16610787

  • 21. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
    von Rauch M, Busch S, Gust R.
    J Med Chem; 2005 Jan 27; 48(2):466-74. PubMed ID: 15658860
    [Abstract] [Full Text] [Related]

  • 22. The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands.
    Wilkening RR, Ratcliffe RW, Tynebor EC, Wildonger KJ, Fried AK, Hammond ML, Mosley RT, Fitzgerald PM, Sharma N, McKeever BM, Nilsson S, Carlquist M, Thorsell A, Locco L, Katz R, Frisch K, Birzin ET, Wilkinson HA, Mitra S, Cai S, Hayes EC, Schaeffer JM, Rohrer SP.
    Bioorg Med Chem Lett; 2006 Jul 01; 16(13):3489-94. PubMed ID: 16632357
    [Abstract] [Full Text] [Related]

  • 23. Synthesis and evaluation of 17alpha-20E-21-(4-substituted phenyl)-19-norpregna-1,3,5(10),20-tetraene-3,17beta-diols as probes for the estrogen receptor alpha hormone binding domain.
    Hanson RN, Lee CY, Friel CJ, Dilis R, Hughes A, DeSombre ER.
    J Med Chem; 2003 Jul 03; 46(14):2865-76. PubMed ID: 12825929
    [Abstract] [Full Text] [Related]

  • 24. Lessons learnt from structural studies of the oestrogen receptor.
    Pike AC.
    Best Pract Res Clin Endocrinol Metab; 2006 Mar 03; 20(1):1-14. PubMed ID: 16522516
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Synthesis and biological evaluation of phenolic 4,5-dihydroisoxazoles and 3-hydroxy ketones as estrogen receptor alpha and beta agonists.
    Poutiainen PK, Venäläinen TA, Peräkylä M, Matilainen JM, Väisänen S, Honkakoski P, Laatikainen R, Pulkkinen JT.
    Bioorg Med Chem; 2010 May 15; 18(10):3437-47. PubMed ID: 20430632
    [Abstract] [Full Text] [Related]

  • 29. Synthesis of anthranylaldoxime derivatives as estrogen receptor ligands and computational prediction of binding modes.
    Tuccinardi T, Bertini S, Martinelli A, Minutolo F, Ortore G, Placanica G, Prota G, Rapposelli S, Carlson KE, Katzenellenbogen JA, Macchia M.
    J Med Chem; 2006 Aug 10; 49(16):5001-12. PubMed ID: 16884312
    [Abstract] [Full Text] [Related]

  • 30. Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative diseases.
    Zhao L, Brinton RD.
    J Med Chem; 2005 May 19; 48(10):3463-6. PubMed ID: 15887952
    [Abstract] [Full Text] [Related]

  • 31. Indazole estrogens: highly selective ligands for the estrogen receptor beta.
    De Angelis M, Stossi F, Carlson KA, Katzenellenbogen BS, Katzenellenbogen JA.
    J Med Chem; 2005 Feb 24; 48(4):1132-44. PubMed ID: 15715479
    [Abstract] [Full Text] [Related]

  • 32. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
    Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC, Harris HA.
    J Med Chem; 2004 Oct 07; 47(21):5021-40. PubMed ID: 15456246
    [Abstract] [Full Text] [Related]

  • 33. Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites.
    De Angelis M, Stossi F, Waibel M, Katzenellenbogen BS, Katzenellenbogen JA.
    Bioorg Med Chem; 2005 Dec 01; 13(23):6529-42. PubMed ID: 16099659
    [Abstract] [Full Text] [Related]

  • 34. Target specific virtual screening: optimization of an estrogen receptor screening platform.
    Knox AJ, Meegan MJ, Sobolev V, Frost D, Zisterer DM, Williams DC, Lloyd DG.
    J Med Chem; 2007 Nov 01; 50(22):5301-10. PubMed ID: 17918820
    [Abstract] [Full Text] [Related]

  • 35. ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.
    Vu AT, Cohn ST, Manas ES, Harris HA, Mewshaw RE.
    Bioorg Med Chem Lett; 2005 Oct 15; 15(20):4520-5. PubMed ID: 16098741
    [Abstract] [Full Text] [Related]

  • 36. Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands.
    Clegg NJ, Paruthiyil S, Leitman DC, Scanlan TS.
    J Med Chem; 2005 Sep 22; 48(19):5989-6003. PubMed ID: 16162002
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Design of a highly selective and potent class of non-planar estrogen receptor β agonists.
    Sundén H, Ma JN, Hansen LK, Gustavsson AL, Burstein ES, Olsson R.
    ChemMedChem; 2013 Aug 22; 8(8):1283-94. PubMed ID: 23784708
    [Abstract] [Full Text] [Related]

  • 39. Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta.
    Minutolo F, Bellini R, Bertini S, Carboni I, Lapucci A, Pistolesi L, Prota G, Rapposelli S, Solati F, Tuccinardi T, Martinelli A, Stossi F, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA, Macchia M.
    J Med Chem; 2008 Mar 13; 51(5):1344-51. PubMed ID: 18269232
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.